Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03279185 · ClinicalTrials.gov registry record

Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite

A clinical trial of HIV/AIDS, sponsored by Harvard School of Public Health (HSPH).

Completed
Registry status
334
Enrollment target
9
Study locations

NCT03279185 is a study of HIV/AIDS that has completed, run by Harvard School of Public Health (HSPH). The registered enrollment target is 334 participants, below the 33,175-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03279185, a study of HIV/AIDS, has completed, sponsored by Harvard School of Public Health (HSPH).

COMPLETED
Registry status
334 participants
Enrollment target
9
Study locations

Study Summary

This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition to adulthood.

Conditions Studied

Study Locations (9)

California

  • University of Southern California - Los Angeles
  • David Geffen School of Medicine at UCLA - Los Angeles

New York

  • New York University School of Medicine - New York
  • SUNY Stony Brook - Stony Brook

Georgia

  • Emory University School of Medicine - Atlanta

Illinois

  • Rush University Cook County Hospital Chicago - Chicago

Maryland

  • Johns Hopkins University - Baltimore

Massachusetts

  • Boston Medical Center - Boston

Washington

  • Seattle Children's Hospital - Seattle

Trial Details

FieldValue
Enrollment Target 334 participants
Start Date 2017-11-01
Est. Completion 2025-05-31

What the Registry Record Tells You About NCT03279185

The ClinicalTrials.gov registry entry for NCT03279185 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 33,175-participant average among 61 other HIV/AIDS trials with a reported enrollment target (99% lower). The listed sponsor is Harvard School of Public Health (HSPH), which has 40 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV/AIDS appearing as the primary indexed condition, and to 0 interventions.

NCT03279185 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, New York, Georgia.

Frequently Asked Questions

What is clinical trial NCT03279185 about?

NCT03279185 is a clinical study titled "Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite". This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition to adulthood.

What is the current status of trial NCT03279185?

This trial is currently completed. The enrollment target is 334 participants. The study started on 2017-11-01. Estimated completion is 2025-05-31.

What conditions does trial NCT03279185 study?

This clinical trial studies the following conditions: HIV/AIDS.

Who is sponsoring clinical trial NCT03279185?

This trial is sponsored by Harvard School of Public Health (HSPH), which has 40 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03279185 being conducted?

This trial has 9 study locations across California, Georgia, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV/AIDS

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.